Caplyta

Pharma

How J&J CEO broke a stalemate and won Intra-Cellular in M&A push

J&J’s proposed $14.6 billion purchase of Intra-Cellular Therapies was made possible by a key intervention from J&J’s CEO Joaquin Duato, a filing shows.

Angus Liu Feb 7, 2025 11:24am

J&J acquires CNS specialist Intra-Cellular for $14.6B

Jan 13, 2025 10:29am

schizophrenia mental health brain neurodegenerative

Intra-Cellular's unstoppable Caplyta nails another trial

Nov 5, 2024 10:15am

Intra-Cellular closing in on major depression nod for Caplyta

Jun 18, 2024 11:40am

A concept image to illustrate mental health medications Models of a pink brain and two white pills which are about the size

Intra-Cellular moves closer to Caplyta depression expansion

Apr 16, 2024 2:27pm

A screenshot from Intra-Cellular Therapies Caplyta Dawn Poolout ad

Intra-Cellular re-ups winning ad as bipolar drug builds momentum

Aug 8, 2023 12:51pm